Cardio Diagnostics to Showcase AI-Powered Heart Risk Solutions at National Benefits Conferences
Cardio Diagnostics Holdings will exhibit at four national benefits conferences in June, presenting AI-driven tools to help employers and plan administrators reduce cardiovascular disease costs and improve workforce health.
Cardio Diagnostics Holdings (NASDAQ: CDIO) announced it will exhibit at four national benefits conferences in June to engage employers, brokers, union trustees, and plan administrators on strategies to address cardiovascular disease, a leading driver of health plan costs and workforce productivity losses. The company will showcase its AI-powered cardiovascular risk assessment offerings, including Epi+Gen CHD, PrecisionCHD, and the HeartRisk population insights platform, designed to identify at-risk individuals earlier and help benefits decision-makers better manage healthcare costs and outcomes.
Cardiovascular disease remains the leading cause of death globally and a major contributor to rising healthcare expenditures for employers. According to the American Heart Association, heart disease and stroke cost the U.S. health system over $200 billion annually, with indirect costs from lost productivity adding further strain. By focusing on early detection and personalized risk assessment, Cardio Diagnostics aims to shift the paradigm from reactive treatment to proactive prevention, potentially reducing both clinical and economic burdens.
The company's offerings are built on a proprietary Artificial Intelligence-driven Integrated Genetic-Epigenetic Engine, which analyzes genetic and epigenetic markers to provide a comprehensive risk profile. Epi+Gen CHD and PrecisionCHD are clinical tests that assess coronary heart disease risk, while HeartRisk is a population-level analytics tool that helps employers and plan administrators identify high-risk groups and tailor interventions. These tools could enable more targeted wellness programs and better allocation of healthcare resources.
The conferences provide a platform for Cardio Diagnostics to connect with key decision-makers in employee benefits, including brokers and union trustees who influence health plan design. As employers seek ways to contain costs while improving employee health, precision medicine approaches like those offered by Cardio Diagnostics are gaining attention. The company's participation underscores a broader trend of integrating advanced diagnostics into corporate wellness strategies.
For more information, the full press release is available at https://ibn.fm/qFRHu. Additional updates and news regarding Cardio Diagnostics can be found in the company’s newsroom at https://ibn.fm/CDIO.
This announcement comes at a time when cardiovascular disease is a top concern for employers. The ability to identify at-risk individuals before symptoms appear could lead to significant savings and better health outcomes. Cardio Diagnostics' AI-powered approach represents a step forward in leveraging technology to address one of the most pressing health challenges facing the workforce today.